Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry / other Cancer Research Results

Amla, Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry: Click to Expand ⟱
Features:

Phyllanthus emblica / Amla / Indian Gooseberry/Emblica officinalis — Phyllanthus emblica L. is the currently accepted botanical name for Amla or Indian Gooseberry; Emblica officinalis Gaertn. is a widely used botanical synonym commonly encountered in older pharmacological and Ayurvedic literature.

Type: Botanical extract / polyphenol-rich medicinal fruit

Active Constituents: Emblicanins, gallic acid, ellagic acid, tannins, flavonoids, vitamin C, and related polyphenolic compounds.

Function: Emblica officinalis extracts exhibit antioxidant, anti-inflammatory, metabolic, cytoprotective, and immunomodulatory activities. Experimental studies also demonstrate effects on apoptosis, proliferation, oxidative stress, inflammatory signaling, and mitochondrial function.

Cancer: Experimental studies report inhibition of tumor-cell proliferation, induction of apoptosis, suppression of inflammation and oxidative signaling, and modulation of pathways involved in invasion, angiogenesis, and tumor progression.

Alzheimer's Disease: Experimental neuroprotective evidence includes reduction of oxidative stress, neuroinflammation, mitochondrial dysfunction, and cognitive impairment in models relevant to neurodegeneration.

Triphala = ~⅓ Amla + ~⅓ Haritaki + ~⅓ Bibhitaki

Amla — Phyllanthus emblica L. is an edible medicinal fruit and polyphenol-rich botanical used in Ayurvedic medicine and as a food and natural health product. It is formally classified as a botanical food/nutraceutical and plant extract rather than an approved anticancer drug. Major constituents include hydrolysable tannins and ellagitannins such as emblicanins, punigluconin and related tannins, together with gallic acid, ellagic acid, flavonoids, quercetin derivatives and vitamin C. Extract composition varies substantially with cultivar, fruit processing and extraction method; therefore whole-fruit powder, aqueous extract and standardized polyphenol extracts should not be considered pharmacologically interchangeable.

Primary mechanisms (ranked):

  1. Antiproliferative and programmed-cell-death signaling, including Fas/death-receptor → caspase-8 → caspase-3/7 apoptosis in responsive cancer models.
  2. Autophagy induction through ↑ Beclin-1 and ↑ LC3B-II, particularly demonstrated in ovarian cancer cells and xenografts.
  3. Anti-angiogenic signaling with ↓ HIF-1α, ↓ tumor microvessel density and suppression of pro-angiogenic gene expression.
  4. Suppression of tumor invasion, migration and metastatic phenotypes, including inhibition of invasive breast-cancer-cell behavior.
  5. miR-375-mediated suppression of pro-angiogenic signaling in ovarian cancer models.
  6. Antioxidant and anti-inflammatory modulation, generally producing ↓ ROS/oxidative damage and ↓ NF-κB/AP-1-related inflammatory signaling in non-malignant or injury models; ROS direction in cancer cells is extract- and model-dependent and should not be treated as a universal pro-oxidant anticancer mechanism.
  7. Chemosensitization, including enhanced antiproliferative/autophagic effects with cisplatin in ovarian cancer models.
  8. Chemopreventive modulation of carcinogen-induced oxidative injury and carcinogen-metabolizing pathways in animal models.

Bioavailability / PK relevance: Oral amla is extensively transformed rather than circulating as an intact botanical extract. Ellagitannins and related polyphenols undergo gastrointestinal and microbiome metabolism, with urolithin conjugates among reported systemic metabolites. Human trials demonstrate biological activity after approximately 500–1000 mg/day standardized extracts, but there is no validated human pharmacokinetic exposure corresponding directly to the whole-extract concentrations used in cancer-cell experiments. Extract standardization and phytochemical composition are major translational variables.

In-vitro vs systemic exposure relevance: Many anticancer studies use approximately 25–300 µg/mL of whole amla extract. These concentrations cannot be directly equated with achievable plasma concentrations because the extract is a complex mixture whose tannins and polyphenols undergo extensive digestion, metabolism and conjugation. Accordingly, direct systemic reproduction of common in-vitro whole-extract exposure is unproven and likely overstates exposure to unchanged parent constituents. Xenograft and carcinogenesis studies provide stronger translational support than cell culture alone, but remain preclinical.

Clinical evidence status: Cancer evidence is preclinical. Antiproliferative, apoptotic, autophagic, anti-invasive and anti-angiogenic activity has been demonstrated in cultured cancer cells and several animal tumor models, but there is no established randomized clinical evidence showing that amla treats human cancer or improves cancer survival. Human RCTs exist for dyslipidemia, endothelial/metabolic endpoints and gastrointestinal disorders and provide useful safety information rather than anticancer efficacy. Amla is recognized by Health Canada as a natural health product ingredient and whole/minimally processed fruit has a history of safe food use; this does not constitute authorization as a cancer treatment.

Amla Cancer-Relevant Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Fas death-receptor apoptosis ↑ Fas
↑ caspase-8
↑ caspase-3/7
↑ apoptosis		 ↔ or cytoprotective (context-dependent) Induction of programmed cancer-cell death Directly demonstrated with aqueous P. emblica extract in HeLa cells. Caspase-9 was not significantly activated in the principal study, supporting predominantly extrinsic rather than mitochondrial initiation.
2 Autophagy Beclin-1 LC3B ↑ Beclin-1
↑ LC3B-II
↑ autophagy		 Context-dependent Growth suppression through autophagic response Strongly demonstrated in ovarian cancer cells and mouse xenografts. In that model, amla suppressed proliferation without prominent apoptosis, illustrating cancer-type-dependent mechanism selection.
3 HIF-1α angiogenesis axis ↓ HIF-1α
↓ angiogenic genes
↓ CD31-positive vessels		 Not established Suppression of tumor angiogenesis Demonstrated in ovarian cancer cells and xenografts; one of the stronger in-vivo-supported anticancer mechanisms.
4 Cell proliferation and tumor growth ↓ proliferation
↓ clonogenic growth
↓ xenograft growth		 Relatively spared in selected models Direct growth inhibition Activity has been reported across lung, liver, cervical, breast, ovarian and colorectal cancer cell lines. Selectivity is incomplete but normal MRC5 fibroblasts and placental cells showed substantially less toxicity in individual studies.
5 Invasion and metastatic phenotype ↓ invasion
↓ migratory phenotype		 Not established Reduced invasive potential Aqueous extract inhibited MDA-MB-231 breast cancer cell invasion at lower concentrations than those used in several proliferation studies.
6 miR-375 pro-angiogenic signaling ↑ miR-375
↓ pro-angiogenic signaling		 Not established Epigenetic suppression of angiogenic signaling Reported in ovarian cancer cells and their exosomes; mechanistically useful but currently narrower in evidence base than HIF-1α suppression.
7 Cisplatin chemosensitization ↑ cisplatin antiproliferative effect
↑ autophagy		 Insufficient evidence Potential chemotherapy sensitization Synergistic activity was reported in ovarian cancer cells. This remains preclinical and should not be interpreted as evidence supporting clinical co-administration.
8 Inflammatory NF-κB AP-1 signaling ↓ inflammatory signaling (context-dependent) ↓ NF-κB
↓ AP-1
↓ inflammatory mediators		 Anti-inflammatory and cytoprotective modulation Mechanistically well supported in non-malignant oxidative-injury models. Direct causal importance to tumor killing is less established than apoptosis, autophagy or angiogenesis.
9 Oxidative stress and ROS ↔ / ↓ / occasionally ↑ downstream stress (model-dependent) ↓ ROS
↓ oxidative damage
↑ antioxidant defenses		 Redox modulation Amla should primarily be classified as an antioxidant botanical. Unlike Triphala, for which ROS-dependent cancer-cell killing has been demonstrated, isolated amla extract does not have sufficiently consistent evidence to assign universal ROS ↑ in cancer cells.
10 Carcinogenesis and tumor promotion ↓ tumor initiation/promotion
↓ tumor burden		 ↓ carcinogen-associated oxidative and tissue injury Chemoprevention Animal studies report reduced chemically induced tumor incidence, number and volume. These models support chemoprevention more strongly than treatment of established human cancer.
11 Clinical Translation Constraint Whole-extract concentrations commonly 25–300 µg/mL in vitro Human oral use generally tolerated in short-term studies Limits direct translation of experimental anticancer activity Extract heterogeneity, extensive polyphenol metabolism, uncertain tumor exposure, lack of oncology RCTs and absence of validated cancer dosing are the principal limitations.


Alzheimer's disease relevance: Amla has meaningful but exclusively preclinical neurodegeneration evidence. Tannoid principles of Emblica officinalis have improved cognition and attenuated biochemical and neuropathological abnormalities in experimental Alzheimer's-like models. Reported mechanisms include ↓ oxidative stress, ↓ neuroinflammation, protection of neuronal and mitochondrial function, modulation of tau-associated pathology and improvement of endogenous antioxidant defenses. More recent preclinical work also implicates autophagy and gut-microbiome modulation. There is no established clinical evidence that amla prevents or treats Alzheimer's disease in humans.

Clinical translation: The evidence supports retention of an AD section in the database, but it should be categorized as preclinical rather than clinical. Effects observed with purified tannoid fractions or polysaccharide fractions should not automatically be assigned quantitatively to generic amla fruit powder or commercial extracts.

Amla Alzheimer-Relevant Mechanisms

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Oxidative stress ↓ ROS-related oxidative injury
↓ lipid peroxidation
↑ antioxidant defenses		 Neuronal protection Among the most reproducible mechanisms in experimental neurodegeneration models.
2 Tau-associated pathology ↓ pathological tau-associated changes Reduced neurodegenerative pathology Reported particularly with isolated tannoid principles of E. officinalis in experimental AD/tau models.
3 Neuroinflammation ↓ inflammatory signaling Reduced neuronal inflammatory injury Likely overlaps with antioxidant and polyphenol-mediated signaling effects.
4 Mitochondrial function ↑ mitochondrial protection
↓ oxidative mitochondrial injury		 Improved neuronal bioenergetic resilience Predominantly preclinical evidence.
5 Autophagy ↑ autophagic regulation (model-dependent) Improved proteostasis and neuronal function Recent polysaccharide work associates cognitive improvement with autophagy modulation and microbiome changes.
6 Cognitive function ↑ learning
↑ memory		 Functional neuroprotection Observed in animal models; human AD efficacy has not been established.
7 Clinical Translation Constraint Preclinical evidence only Limits therapeutic inference No convincing human randomized trial demonstrating prevention or treatment of Alzheimer's disease.


other, other: Click to Expand ⟱
Source:
Type:
custom
Scientific Papers found: Click to Expand⟱
7397- Amla,    Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study
- Trial, Nor, NA
*Dose↝, *other↑, *LDL↓, *HDL↑, *toxicity↑, *ROS↓,
7408- Amla,    Fresh Phyllanthus emblica (Amla) Fruit Supplementation Enhances Milk Fatty Acid Profiles and the Antioxidant Capacities of Milk and Blood in Dairy Cows
- Trial, Nor, NA
*Dose↝, *TAC↑, *SOD↑, *Albumin↑, *ROS↓, *other↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

HDL↑, 1,   ROS↓, 2,   SOD↑, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

Albumin↑, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↑, 1,  
Total Targets: 9

Scientific Paper Hit Count for: other, other
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:442  Target#:767  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page